BRPI0908455A2 - formulações de flibanserina - Google Patents

formulações de flibanserina

Info

Publication number: BRPI0908455A2
Authority: BR; Brazil
Prior art keywords: flibanserin; formulations; flibanserin formulations
Prior art date: 2008-02-13

Application number

BRPI0908455A

Other languages

English (en)

Inventor

Julia Boni

Karl Gerhard Wagner

Rolf-Stefan Brickl

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-13

Filing date

2009-02-11

Publication date

2015-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908455(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-11 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-12-15 Publication of BRPI0908455A2 publication Critical patent/BRPI0908455A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0908455A 2008-02-13 2009-02-11 formulações de flibanserina BRPI0908455A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08101599A EP2090297A1 (en)	2008-02-13	2008-02-13	Formulations of flibanserin
PCT/EP2009/000941 WO2009100886A2 (en)	2008-02-13	2009-02-11	Formulations of flibanserin

Publications (1)

Publication Number	Publication Date
BRPI0908455A2 true BRPI0908455A2 (pt)	2015-12-15

Family

ID=39431170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908455A BRPI0908455A2 (pt)	2008-02-13	2009-02-11	formulações de flibanserina

Country Status (13)

Country	Link
US (3)	US20110045090A1 (pt)
EP (2)	EP2090297A1 (pt)
JP (1)	JP2011511818A (pt)
CN (1)	CN101951894A (pt)
AR (1)	AR070367A1 (pt)
BR (1)	BRPI0908455A2 (pt)
CA (1)	CA2714542A1 (pt)
CL (1)	CL2009000322A1 (pt)
IL (1)	IL206577A0 (pt)
MX (1)	MX2010008852A (pt)
PE (1)	PE20091418A1 (pt)
TW (1)	TW200940057A (pt)
WO (1)	WO2009100886A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012162492A1 (en) *	2011-05-24	2012-11-29	Teva Pharmaceutical Industries Ltd.	Compressed core comprising organic acids for a pharmaceutical composition
DK3148513T3 (da)	2014-05-29	2020-05-25	Novartis Ag	Ceritinib-formulering
CN104926734B (zh) *	2015-07-07	2017-04-05	苏州立新制药有限公司	氟班色林的制备方法
WO2017026950A1 (en) *	2015-08-07	2017-02-16	Santa Farma Ilac San. A. S.	Controlled release propiverine formulations
WO2017055935A1 (en) *	2015-09-30	2017-04-06	Symed Labs Limited	Amorphous co-precipitates of flibanserin
CN106866546A (zh) *	2015-12-10	2017-06-20	常州爱诺新睿医药技术有限公司	氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN110251475B (zh) *	2019-07-25	2021-07-16	沈阳信康药物研究有限公司	一种帕利哌酮片剂及其制备方法
KR102816429B1 (ko) *	2020-12-31	2025-06-04	서울대학교 산학협력단	퇴행성 신경질환 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1251144B (it)	1991-07-30	1995-05-04	Boehringer Ingelheim Italia	Derivati del benzimidazolone
DE19961334A1 (de) *	1999-12-17	2001-06-21	Roehm Gmbh	Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
JP3822601B2 (ja)	2001-08-02	2006-09-20	ビダケムソシエタペルアチオニ	安定多形体のフリバンセリン、その製造方法及び薬剤を製造するためのその使用
DE10209982A1 (de) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma	Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
BRPI0311189B8 (pt) *	2002-05-22	2021-05-25	Boehringer Ingelheim Pharma	composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
CA2573705A1 (en) *	2004-07-29	2006-02-02	Sanofi-Aventis	Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
CA2578626C (en) *	2005-06-27	2011-07-19	Biovail Laboratories International S.R.L.	Modified-release formulations of a bupropion salt
FR2887455B1 (fr) *	2005-06-28	2007-08-10	Sanofi Aventis Sa	Formulation a liberation prolongee de principes actifs de medicaments
EP1940357A2 (en) *	2005-09-30	2008-07-09	SmithKline Beecham Corporation	Pharmaceutical compositions
RU2490012C2 (ru) *	2006-01-27	2013-08-20	Апталис Фарматех Инк	Системы доставки лекарственного средства, содержащие слабощелочной селективный 5-ht3, серотониновый блокатор и органические кислоты
CA2660476C (en) *	2006-08-14	2015-11-17	Boehringer Ingelheim International Gmbh	Formulations of flibanserin and method for manufacturing the same
CN101505736A (zh) *	2006-08-25	2009-08-12	贝林格尔.英格海姆国际有限公司	控制释放系统及其制造方法
US8486452B2 (en) *	2007-07-20	2013-07-16	Mylan Pharmaceuticals Inc.	Stabilized tolterodine tartrate formulations

2008
- 2008-02-13 EP EP08101599A patent/EP2090297A1/en not_active Withdrawn
2009
- 2009-02-11 CN CN2009801052034A patent/CN101951894A/zh active Pending
- 2009-02-11 CA CA2714542A patent/CA2714542A1/en not_active Abandoned
- 2009-02-11 US US12/867,097 patent/US20110045090A1/en not_active Abandoned
- 2009-02-11 MX MX2010008852A patent/MX2010008852A/es not_active Application Discontinuation
- 2009-02-11 PE PE2009000195A patent/PE20091418A1/es not_active Application Discontinuation
- 2009-02-11 WO PCT/EP2009/000941 patent/WO2009100886A2/en active Application Filing
- 2009-02-11 BR BRPI0908455A patent/BRPI0908455A2/pt not_active IP Right Cessation
- 2009-02-11 JP JP2010546257A patent/JP2011511818A/ja active Pending
- 2009-02-11 EP EP09709701A patent/EP2252270A2/en not_active Withdrawn
- 2009-02-12 AR ARP090100504A patent/AR070367A1/es unknown
- 2009-02-12 CL CL2009000322A patent/CL2009000322A1/es unknown
- 2009-02-12 TW TW098104529A patent/TW200940057A/zh unknown
2010
- 2010-06-23 IL IL206577A patent/IL206577A0/en unknown
2012
- 2012-10-22 US US13/657,147 patent/US20130209519A1/en not_active Abandoned
2014
- 2014-12-15 US US14/570,467 patent/US20150224058A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2714542A1 (en)	2009-08-20
US20150224058A1 (en)	2015-08-13
AR070367A1 (es)	2010-03-31
US20130209519A1 (en)	2013-08-15
EP2252270A2 (en)	2010-11-24
WO2009100886A2 (en)	2009-08-20
EP2090297A1 (en)	2009-08-19
PE20091418A1 (es)	2009-10-07
TW200940057A (en)	2009-10-01
CN101951894A (zh)	2011-01-19
WO2009100886A3 (en)	2009-11-26
CL2009000322A1 (es)	2010-03-05
US20110045090A1 (en)	2011-02-24
MX2010008852A (es)	2010-09-24
JP2011511818A (ja)	2011-04-14
IL206577A0 (en)	2010-12-30

Publication	Publication Date	Title
HRP20181347T1 (hr)	2018-10-19	Formulacije dvoslojne tablete
BRPI0908785A2 (pt)	2015-07-28	Formulações herbicida
BRPI0912213A2 (pt)	2015-10-06	preparação cosmética
EP2296593A4 (en)	2015-01-14	MEDICAL HEAD COVER
EP2263545A4 (en)	2011-05-04	sonographer
BRPI0921327A2 (pt)	2015-08-25	Combinação de herbicida-protetor
DE602009000580D1 (de)	2011-03-03	Endoskopsystem
BRPI0814188A2 (pt)	2014-10-14	Formulações
BRPI0918249A2 (pt)	2015-12-15	prótese
HUE054030T2 (hu)	2021-08-30	Fejlesztett formulációk
BRPI0908455A2 (pt)	2015-12-15	formulações de flibanserina
BRPI0922728A2 (pt)	2019-09-24	combinação de herbicida-antídoto
BRPI0920833A2 (pt)	2015-12-22	preparação de benzonorborbenos
EP2467136A4 (en)	2013-01-16	4-methylpyrazole FORMULATIONS
BRPI0823402A2 (pt)	2015-06-16	Formulações farmacêuticas de olmesartan
DE112009003312A5 (de)	2013-09-26	Implantat
FI20085670A0 (fi)	2008-06-30	Kiinnirullain
PT2376075E (pt)	2015-06-08	Formulações nasais de metoclopramida
FI20085741A7 (fi)	2010-01-24	Kuvantamisjärjestely
UA18855S (uk)	2009-05-12	Гіпертермотерапевтичне крісло
FR2937843B1 (fr)	2010-12-24	Paravent medical
FI20095422A0 (fi)	2009-04-17	Kiinnirullain
DE602009000508D1 (de)	2011-02-17	Implantat
FI20080012A0 (fi)	2008-01-08	Farmaseuttiset formulaatiot
FI20080013A0 (fi)	2008-01-08	Uudet farmaseuttiset formulaatiot

Legal Events

Date	Code	Title	Description
2016-09-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A E 7A ANUIDADES.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.